Nalmefene Products Clause Samples

Nalmefene Products. As partial consideration for the grant to OPIANT of the rights under Section 3.1 the Parties agree to the following milestones for the first Product containing nalmefene: Successful Completion of the first pilot PK study in humans [***] Upon the Successful Completion of the first PK study in humans; provided, that if OPIANT has not initiated a first PK study in humans by September 30, 2018, then such milestone shall be due on September 30, 2018 [***] Approval of the first NDA or its equivalent [***] At the time when any milestone payment listed in the table above is due, if OPIANT has not paid all other milestone payments (if any) previously listed in such table, then at such time OPIANT shall pay all such unpaid previous milestone payments.